

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 58117

Manuscript Type: CASE REPORT

Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports

Cory Higley, Christine C Hsu, Coleman Smith, Sandeep Nadella, Alexander Lalos

Abstract

BACKGROUND

Direct-acting antiviral (DAA) therapy regimens are highly effective at eliminating hepatitis C virus (HCV) infection but rates of sustained virologic response (SVR) rates are lower in patients with decompensated cirrhosis or hepatocellular carcinoma. Since many of these patients will be referred for liver transplant, they will require retreatment

Match Overview



- | | | |
|---|--|----|
| 1 | Internet 90 words
crawled on 18-Apr-2020
aasldpubs.onlinelibrary.wiley.com | 3% |
| 2 | Crossref 17 words
Maria G. Cardona-Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley. "Sofosbuvir, V | 1% |

Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-li



ALL

IMAGES

VIDEOS

9,100 Results

Any time ▼

Effectiveness and safety of sofosbuvir/velpatasvir ...

<https://www.sciencedirect.com/science/article/pii/S0168827819303459>

Oct 01, 2019 · , , Despite the high **efficacy** of these new combinations, the options for **patients** who do not achieve a sustained virological response (SVR) are limited. 8 The latest approved retreatment regimen is combined therapy with **sofosbuvir** plus the NS5B inhibitor, **velpatasvir**, and the NS3/4 protease inhibitor, **voxilaprevir** (SOF/VEL/VOX), 9 which is ...

Cited by: 8**Author:** Jordi Llaneras, Mar Riveiro-Barciela, Sa...**Publish Year:** 2019

Real-life effectiveness and safety of sofosbuvir ...

<https://www.sciencedirect.com/science/article/pii/S0168827819304611>

Dec 01, 2019 · SOF/VEL/VOX demonstrated excellent effectiveness in **patients** with HCV and **previous DAA failure** in a real-life study. • Cirrhosis ($p = 0.005$) and hepatocellular carcinoma onset ($p = 0.02$) were the only features associated with treatment **failure**. Treatment failures (4%) occurred in **patients** with cirrhosis, with genotypes HCV-1a and 3 the most represented.

Cited by: 8**Author:** Elisabetta Degasperi, Angiola Spinetti, ...**Publish Year:** 2019

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287482>

Sofosbuvir, **Velpatasvir**, and **Voxilaprevir** for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation ... Further study is needed to establish **safety and efficacy** and define treatment duration in difficult-to-treat populations. ... ($\geq 95\%$ sustained virologic response at 12 weeks [SVR12]) in phase 3 studies in **DAA** ...

Author: Maria G. Cardona-Gonzalez, Jason ...**Publish Year:** 2018

PEOPLE ALSO ASK

ALL

IMAGES

VIDEOS

7,800 Results

Any time ▼

Effectiveness and safety of sofosbuvir/velpatasvir ...

<https://www.sciencedirect.com/science/article/pii/S0168827819303459>

Oct 01, 2019 · , Despite the high **efficacy** of these new combinations, the options for **patients** who do not achieve a sustained virological response (SVR) are limited. 8 The latest approved retreatment regimen is combined therapy with **sofosbuvir** plus the NS55 inhibitor, **velpatasvir**, and the NS3/4 protease inhibitor, **voxilaprevir** (SOF/VEL/VOX), 9 which is ...

Cited by: 9

Author: Jordi Llaneras, Mar Riveiro-Barciela, Sabela...

Publish Year: 2019

Effectiveness and safety of sofosbuvir/velpatasvir ...

<https://ejhp.bmj.com/content/27/e1/e41> ▼

Mar 01, 2020 · The outcome variable of effectiveness was sustained virological response 12 weeks after completing treatment (SVR12). The **safety** variable was withdrawal secondary to severe adverse events (SAEs). Covariates included sex, age, HIV co-infection, **previous** liver **transplant**, cirrhosis, hepatic fibrosis and **previous antiviral** treatment.

Author: Luis Margusino-Framiñán, Purificación ...

Publish Year: 2020

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1613512>

In two trials involving **patients** with hepatitis C in whom **previous** treatment with **direct-acting antiviral** agents failed, treatment for 12 weeks with **sofosbuvir**, **velpatasvir**, and **voxilaprevir** achiev...

Cited by: 443

Author: Marc Bourlière, Stuart C. Gordon, Steven L. ...

Publish Year: 2017

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1280>

Nov 14, 2018 · This brief report details the experience of a **post-liver transplant** patient with recurrent hepatitis C genotype 3 infection. The patient was successfully treated with **sofosbuvir**, **velpatasvir**...

Cited by: 1

Author: Maria G. Cardona-Gonzalez, Jason D. Gold...

Publish Year: 2018

Real-life effectiveness and safety of sofosbuvir ...

<https://www.sciencedirect.com/science/article/pii/S0168827819304611>

Dec 01, 2019 · Introduction. The development of **direct-acting** antivirals (DAA) for the treatment of HCV has dramatically increased rates of sustained virological response (SVR) to **antiviral** therapy, reaching more than 95–98% in all patient groups. 1 Despite optimal **efficacy** and **safety**, approximately 2% of **patients** still fail to achieve an SVR and need alternative treatment options. 1 Retreatment of ...



ALL

IMAGES

VIDEOS

7,790 Results

Any time ▾

Effectiveness and safety of sofosbuvir/velpatasvir ...

<https://www.sciencedirect.com/science/article/pii/S0168827819303459>

Oct 01, 2019 · , , Despite the high **efficacy** of these new combinations, the options for **patients** who do not achieve a sustained virological response (SVR) are limited. 8 The latest approved retreatment regimen is combined therapy with **sofosbuvir** plus the NS55 inhibitor, **velpatasvir**, and the NS3/4 protease inhibitor, **voxilaprevir** (SOF/VEL/VOX), 9 which is ...

Cited by: 9**Author:** Jordi Llaneras, Mar Riveiro-Barciela, Sab...**Publish Year:** 2019

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1613512>

In two trials involving **patients** with hepatitis C in whom **previous** treatment with **direct-acting antiviral** agents failed, treatment for 12 weeks with **sofosbuvir**, **velpatasvir**, and **voxilaprevir** achiev...

Cited by: 443**Author:** Marc Bourlière, Stuart C. Gordon, Steven...**Publish Year:** 2017

Effectiveness and safety of sofosbuvir/velpatasvir ...

<https://ejhp.bmj.com/content/27/e1/e41> ▾

Mar 01, 2020 · The outcome variable of effectiveness was sustained virological response 12 weeks after completing treatment (SVR12). The **safety** variable was withdrawal secondary to severe adverse events (SAEs). Covariates included sex, age, HIV co-infection, **previous** liver **transplant**, cirrhosis, hepatic fibrosis and **previous antiviral** treatment.

Author: Luis Margusino-Framiñán, Purificació...**Publish Year:** 2020

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1280>

Nov 14, 2018 · This brief report details the experience of a **post-liver transplant** patient with recurrent hepatitis C genotype 3 infection. The patient was successfully treated with **sofosbuvir**, **velpatasvir**...

Cited by: 1**Author:** Maria G. Cardona-Gonzalez, Jason D. G...**Publish Year:** 2018